Iovance Reports Durable Lifileucel Responses in Soft Tissue Sarcomas
Iovance reported a 50% confirmed objective response rate, with all responses ongoing. The data were presented at ESMO 2026.
Iovance reported a 50% confirmed objective response rate, with all responses ongoing. The data were presented at ESMO 2026.